Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow of -$556K in Q2 FY2026
Q2 FY2026 financing cash flow was -$556K.
Context
- Financing cash flow amounted to 10519.4% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 142.01M USD
- Year-over-year change
- +71.6%
- 1-year CAGR
- +71.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 142.01M | +71.6% |
| FY2024 | 2024-12-31 | 82.75M | — |
Financing Cash Flow vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 financing cash flow of $142.01M is the 4th largest of the 10 companies compared; the peer median is $103.52M.
- Its year-over-year change of +71.6% is the 4th highest of 9, against a peer median of +47.0%.
- Financing cash flow amounts to 10519.4% of revenue for ATTO, versus a peer median of 1165.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $830.71M | +390.1% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +53.0% | -72.7% | 4878.8% |
EVMNEvommune, Inc. | LTM Mar 2026 | $338.03M | — | — | 3380.3% |
| FY2025 | $142.01M | +71.6% | — | 10519.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M | +11.1% | — | — |
| LTM Mar 2026 | $103.52M | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $102.81M | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $52.19M | -29.8% | — | 623.8% | |
| LTM Mar 2026 | $5.67M | +234.8% | — | 10.6% | |
| FY2025 | $1.09M | +381.5% | — | 1707.8% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $103.52M | +47.0% | -32.9% | 1165.8% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.